Studies

MK-9999-U01 Master Protocol: A Phase 1/2 Platform Study to Evaluate the Safety and Efficacy of Investigational Agents in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors

Cancer Pediatrics Leukemia Lymphoma Sarcoma Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Lurbinectedin in FET-Fused Tumors

Cancer Pediatrics Leukemia Sarcoma Pediatric Subjects Adult Subjects

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

NMTRC014: Beat Childhood Cancer

Cancer Pediatrics Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects Female Subjects Male Subjects

Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

BCC015 : Beat Childhood Cancer

Cancer Pediatrics Brain and Spinal Cord Cancer Pediatric Subjects Adult Subjects Female Subjects Male Subjects

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.